Actively Recruiting
TMS-related Measures as Biomarker of Cognitive Impairment in PD
Led by Azienda Sanitaria Universitaria Integrata del Trentino · Updated on 2025-12-22
52
Participants Needed
3
Research Sites
172 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline. The main questions it aims to answer are: * TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)? * TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?
CONDITIONS
Official Title
TMS-related Measures as Biomarker of Cognitive Impairment in PD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Ability to undergo an extensive neuropsychological evaluation
- Ability to sign informed consent for the study
- Diagnosed with idiopathic Parkinson's disease according to the latest MDS criteria
- On stable and optimal antiparkinsonian therapy for at least four weeks
You will not qualify if you...
- Significant systemic diseases such as active cancers requiring chemotherapy or end-stage heart failure
- Any active neurological disease other than Parkinson's disease
- Presence of cochlear implant, ferromagnetic brain device near stimulation site, pacemaker, brain electrodes for deep brain stimulation, electromechanical devices with implantable pulse generator, or other implantable stimulators
- History of epilepsy or seizure disorders
- History of cerebrovascular, tumor-related, infectious, or metabolic brain diseases that cause seizures or symptomatic epilepsy
- Pregnancy or breastfeeding
- Alcoholism
- Treatment in the last month with anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics, or antidepressants
- Treatment with drugs that lower seizure threshold, including certain antidepressants, antipsychotics, antivirals, stimulants, and recreational drugs
- Active cochlear disease especially if receiving ototoxic drugs
- Diagnosis of dementia according to the latest MDS criteria for Parkinson's disease dementia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
Trieste, Friuli Venezia Giulia, Italy
Not Yet Recruiting
2
UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto Adige
Sterzing, Trentino-Alto Adige, Italy, 39049
Not Yet Recruiting
3
UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS)
Trento, Trentino-Alto Adige, Italy, 38122
Actively Recruiting
Research Team
R
Ruggero Bacchin, MD
CONTACT
S
Stefania Campostrini, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here